EchoiQ

ASX: EIQ RELEASE 02 July 2026

Strategic Advara partnership provides exclusive access to up to 1 million echocardiography studies to advance product development

- **Binding exclusivity secured through executed definitive exclusive data licensing agreement with Advara HeartCare, Australia's leading private cardiovascular healthcare provider, delivering specialist cardiology services across prevention, diagnostics, treatment, clinical research and data-driven innovation**
- **Data licensing agreement provides Echo IQ access to between 500,000 and 1,000,000 de-identified echocardiography studies and associated relevant clinical datasets**
- **Dataset includes echocardiographic images and linked clinical information across a broad and diverse patient population**
- **Strategic data asset expected to materially enhance future EchoSolv product development, training and validation of next-generation cardiovascular AI products**
- **Highly complementary to Echo IQ's existing National Echo Database Australia (NEDA) relationship, creating one of Australia's most powerful cardiovascular AI data ecosystems**
- **Exclusive access strengthens competitive position and supports expansion of Echo IQ's future product pipeline**
- **Agreement provides for an initial three-year term with an option to extend for a further three years, subject to HREC ethics approval and agreement on data quality specifications**

Sydney: Artificial Intelligence (“AI”) and Medical Technology Company Echo IQ Limited (ASX: EIQ) (“Echo IQ” or “the Company”) is pleased to advise it has executed a definitive exclusive data licensing agreement with Advara HeartCare Pty Ltd (“Advara”), Australia's largest private cardiovascular diagnostics provider, providing Echo IQ exclusive access to one of the country's largest cardiovascular imaging datasets.

Advara operates an extensive national network of cardiovascular clinics and diagnostic facilities, delivering quality echocardiography and other cardiac imaging services across Australia. As Australia's leading private cardiovascular healthcare provider, Advara delivers the full spectrum of cardiovascular services through its national network of cardiologists, specialist clinics, diagnostic services and clinical research programs, supporting more than 750,000 patient interactions annually. Complemented by one of Australia's largest private cardiovascular research programs and extensive real-world clinical datasets, Advara has established itself as a leader in cardiovascular research, evidence generation and responsible healthcare innovation. Through its scale, geographic reach and depth of clinical activity, Advara has developed a substantial repository of real-world cardiovascular imaging and associated clinical information. These data have been generated through routine clinical care and ethically conducted research and are managed under robust clinical governance, privacy and information security frameworks. They represent a valuable strategic resource for advancing cardiovascular research, improving patient care and supporting the responsible development of next-generation artificial intelligence applications in cardiology.

Under the agreement, Echo IQ will receive access, in an exclusive licencing arrangement, to a substantial dataset of de-identified echocardiography studies and associated clinical information sourced through Advara's national network. The dataset is expected to comprise between 500,000 and 1,000,000 de-identified echocardiographic studies, echocardiographic images and associated clinical datasets, subject to final extraction, matching and de-identification processes.

The definitive agreement contains binding exclusivity provisions, comprehensive data quality and de-identification standards, intellectual property protections ensuring Echo IQ retains ownership of all AI outputs, and detailed confidentiality and data security obligations. Initial delivery of licensed data is subject to Human Research Ethics Committee ("HREC") ethics approval and agreement on data quality specifications.

The proposed dataset includes echocardiographic images together with associated clinical information, including de-identified patient demographics where applicable and appropriate, referral pathways, diagnostic findings and relevant clinical outcomes. Access to both large-scale imaging data and linked clinical datasets is expected to significantly enhance Echo IQ's ability to develop, train and validate future AI models across a broad range of cardiovascular conditions.

The Company believes access to large, high-quality imaging datasets will become increasingly important as cardiovascular AI evolves from single-disease applications towards broader multi-condition diagnostic and predictive platforms. The Advara dataset is expected to materially strengthen the Company's future product development capabilities by providing a substantial imaging resources capable of further supporting algorithm development, model refinement and validation activities across multiple cardiovascular indications.

The Advara dataset is also highly complementary to Echo IQ's existing relationship with the National Echo Database Australia ("NEDA"). While NEDA provides one of the world's largest longitudinal cardiovascular outcomes datasets and remains central to Echo IQ's clinical validation, evidence-generation and regulatory strategy, the Advara dataset provides extensive real-world imaging data ideally suited to AI development and model training.

Together, these assets are expected to create a differentiated cardiovascular AI ecosystem spanning product discovery, algorithm development, clinical validation, regulatory evidence generation and commercial deployment.

Echo IQ believes the combination of large-scale imaging datasets and longitudinal clinical outcomes data represents a significant competitive advantage and further strengthens the Company's position as a leading developer of AI-enabled cardiovascular diagnostics. The proposed agreement is expected to support the expansion of Echo IQ's future product pipeline while enhancing the performance and clinical utility of existing and future technologies.

Management commentary:

Advara Chief Executive Officer, Dr David O'Donnell said: *"At Advara HeartCare, our purpose is to improve Australia's heart health through clinical excellence complemented by research and innovation. As Australia's largest cardiology network, Advara HeartCare generates substantial real-world cardiovascular clinical and imaging data which, when appropriately governed and de-identified, can support the responsible development and validation of technologies designed to improve patient care. We are pleased to collaborate with Echo IQ in supporting the development of next-generation AI-enabled cardiovascular imaging applications. At Advara we are focused on continuing to provide world leading care to our patients and we see that AI has the potential to complement the role of the clinician in providing this best quality care to our patients."*

Chief Executive Officer, Mr Dustin Haines said: *"Securing access to a dataset of this scale is strategically important for Echo IQ and represents a significant enhancement to our long-term AI development capabilities.*

While NEDA continues to provide a world-class platform for clinical validation and outcomes research, the Advara dataset brings something different and highly complementary, which centres around large-scale real-world imaging data that can be used to train, refine and develop future generations of cardiovascular AI products. This significantly strengthens our opportunities to expand the EchoSolv platform.

The combination of these two unique data assets significantly strengthens our competitive position, expands our future product development opportunities and reinforces our strategy of building a leading cardiovascular AI platform supported by proprietary and difficult-to-replicate datasets."

- ENDS -

Authorised for release by the Board of Directors of Echo IQ Limited.

Investor Enquiries:

Andrew Grover, Executive Chair
Andrew.grover@echoiq.ai / investor@echoiq.ai

Henry Jordan, Six Degrees Investor Relations
Henry.jordan@sdir.com.au / +61 (0) 431 271 538

ABOUT ECHO IQ

Echo IQ uses AI-driven technology and proprietary software to improve decision making in Cardiology.
The company is based in Sydney, Australia.

FORWARD-LOOKING STATEMENTS

This announcement contains forward-looking statements, including statements regarding the data licensing agreement between Echo IQ and Advara HeartCare, the anticipated size and composition of the dataset, the expected benefits of the arrangement, the development of future EchoSolv products and cardiovascular AI technologies, the expansion of Echo IQ's product pipeline, and the Company's broader growth strategy.

Forward-looking statements are not historical facts and can generally be identified by the use of words such as "expects", "believes", "anticipates", "plans", "intends", "may", "will", "could", "potential", "opportunity", "target", "estimate" and similar expressions.

These forward-looking statements are based on Echo IQ's current expectations, assumptions and beliefs as at the date of this announcement. Actual results, performance or achievements may differ materially from those expressed or implied in such statements due to a range of risks, uncertainties and other factors, many of which are beyond the Company's control.

Key risks include, but are not limited to:

Ethics Approval and Data Specification Risk: Delivery of the Licensed Data under the definitive agreement is subject to Advara obtaining HREC ethics approval and the parties agreeing on data quality specifications. If HREC approval is not obtained within the required timeframe or the parties fail to agree on data quality specifications within 60 days of commencement, Echo IQ may terminate the agreement and recover all licence fees paid. There can be no assurance that ethics approval will be obtained, or that data quality specifications will be agreed, within the anticipated timeframes or at all.

Data Availability and Quality Risk: The anticipated dataset size of between 500,000 and 1,000,000 studies remains subject to final extraction, matching, de-identification, quality review and other technical processes. Advara has warranted that no fewer than 500,000 de-identified echocardiograms will be delivered and that no less than 70% of the licensed data will meet agreed data quality specifications. There can be no assurance that the final dataset will contain the volume, composition or characteristics currently expected.

Product Development Risk: While the Company believes the proposed dataset has the potential to enhance future product development activities, there can be no assurance that access to the dataset will result in the successful development, validation, regulatory approval or commercialisation of any new products, algorithms or technologies.

Regulatory Risk: Future products developed using the proposed dataset may require regulatory approvals, clearances or certifications in relevant jurisdictions. There can be no assurance that any such approvals will be obtained within anticipated timeframes or at all.

Commercialisation Risk: The successful development and commercialisation of future AI-enabled cardiovascular products will depend on a range of factors including clinical performance, regulatory outcomes, customer adoption, reimbursement pathways, competitive dynamics and broader market acceptance.

Data Privacy and Compliance Risk: The arrangement is subject to ongoing compliance with applicable privacy, data protection and healthcare regulations, including the Privacy Act 1988 (Cth), the Australian Privacy Principles and the My Health Records Act 2012 (Cth). Changes in legal, regulatory or compliance requirements could impact the availability or utilisation of data under the agreement.

Data Privacy and Compliance Risk: The proposed arrangement is subject to ongoing compliance with applicable privacy, data protection and healthcare regulations. Changes in legal, regulatory or compliance requirements could impact the availability or utilisation of data under any definitive agreement.

The forward-looking statements contained in this announcement speak only as of the date of this announcement. Except as required by applicable law, the ASX Listing Rules or other regulatory requirements, Echo IQ undertakes no obligation to publicly update or revise any forward-looking statements to reflect subsequent events, circumstances or expectations.